Welcome to the Researcher 2 Researcher Podcast - the Bariatric Surgery Edition series.
------------------
This podcast is made possible by the sponsors
Fengh Europe
Bariatric Solutions International
------------------
In this Podcast, the latest updates from the research on the one (Semaglutide), two (Tirzepatide), and three-function (Retatrutide) anti-obesity drugs with inclusion and exclusion criteria, recent results, the future of bariatric metabolic surgery, and discussions with the experts. 

The distinguished professors are
Prof. Lee Kaplan, USA
Prof. Arya Sharma, Canada

Together with your regular Researcher 2 Researcher host, Dr. Bart Torensma (Clinical epidemiologist & Data Scientist), in collaboration with your co-host Owen Haskins from Bariatric News 
------------------
Used articles in this podcast

1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF;
STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
link to article

2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A;
SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
link to article

3. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML;
Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
 N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972. Epub ahead of print. PMID: 37366315.
link to article

------------------
Questions, comments, want to join the podcast, or new ideas for an episode? 

Email me at:
podcast@researcher2researcher.com